Skip to main content

Table 2 Physical and laboratory measurements in the 2 groups at baseline and 6-month follow-up.

From: Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study

Variable

Group A, Pioglitazone

(n = 42)

Group B, Other treatment

(n = 39)

Comparison of changes between the 2 groups

 

Baseline

Follow-up

P value

Baseline

Follow-up

P value

P value (RM ANOVA)

Body weight, kg

76.6 ± 12.5

78.8 ± 12.9

0.025

74.2 ± 10.8

74.2 ± 11.7

0.50

0.026

Waist, cm

104.7 ± 11.2

104.0 ± 12.0

0.12

105.6 ± 15.9

104.0 ± 10.2

0.63

0.19

Heart rate, beats/min

73 ± 11

72 ± 11

0.58

73 ± 8

71 ± 10

0.08

0.86

Systolic BP, mmHg

143 ± 15

141 ± 15

0.47

150 ± 17

146 ± 18

0.21

0.62

Diastolic BP, mmHg

78 ± 6

75 ± 7

0.003

78 ± 8

79 ± 9

0.64

0.024

Total cholesterol, mg/dl

214 ± 40

224 ± 45

0.000

212 ± 43

226 ± 44

0.019

0.45

Triglycerides, mg/dl

142 ± 60

134 ± 51

0.31

143 ± 94

160 ± 80

0.050

0.030

HDL cholesterol, mg/dl

53 ± 11

56 ± 12

0.002

56 ± 14

53 ± 12

0.017

0.014

LDL cholesterol, mg/dl

134 ± 33

141 ± 39

0.018

125 ± 44

141 ± 39

0.017

0.22

Fasting glucose, mg/dl

154 ± 31

146 ± 31

0.017

153 ± 33

149 ± 29

0.23

0.37

Fasting insulin, μU/ml

9.9 ± 5.2

7.7 ± 3.3

0.000

9.3 ± 4.8

10.2 ± 5.3

0.42

0.006

HbA1C, %

8.0 ± 0.9

7.5 ± 1.0

0.000

7.9 ± 1.0

7.5 ± 1.3

0.002

0.28

Glucose-to-insulin ratio

19.0 ± 10.3

23.5 ± 13.6

0.000

21.4 ± 15.1

22.1 ± 21.1

0.51

0.08

HOMA

3.9 ± 2.6

2.7 ± 1.2

0.000

3.5 ± 1.8

3.6 ± 1.8

0.38

0.001

  1. Mean ± SD. * p < 0.05 compared to group A
  2. BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1C, glycaeted hemoglobin; HOMA, homeostasis model assessment; RM ANOVA, repeated measures analysis of variance.